Consejo Superior De Investigaciones Cientificas

Noscira, S.a.

Neuropharma, S.a.

Other

Instituto Biomar, S.a.

Universidad Autonoma De Madrid (Uam)

Universidad Autónoma De Madrid

Ana Martinez Gil

Mercedes Alonso Cascon

Miguel Medina Padilla

Daniel Ignacio Perez Fernandez

Ana Castro Morera

Isabel Dorronsoro Diaz

Ana Fuertes Huerta

Valle Palomo Ruiz

Francisco Jose Moreno Munoz

Francisco Wandosell Jurado

Paola Usan Egea

Esther Garcia Palomero

Julio Alberto Reyes Rodriguez

Concepcion Perez Martin

Carmen Gil Ayuso-Gontan

Maria Concepcion Martin Perez

Maria Jose Perez Puerto

Laura Rubio Arrieta

Santiago Conde Ruzafa

Carmen Gil Ayuso-gontan

Gema Panizo Del Pliego

Jorge Sánchez-Quesada

Carmen Gil Ayuso-Gontán

María Isabel Loza García

Concepción Perez

Jorge Sanchez Quesada

Maria Concepcion Perez Martin

Loreto Martinez-Gonzalez

Elisa Rojas Prats

Angeles Martin-Requero

Daniel I Perez

Rocio Benitez Fernandez

Josefa Zaldivar Diaz De Bonilla

Pilar Munoz Ruiz

Celia De Austria

Susana Morales-Alcelay

Ana Maria Garcia Fernandez

Concepción Perez Martín

Ana María Perez Castillo

María Isabel Cadavid Torres

José Brea Floriani

Maria Luisa Navarro Rico

Ester Martin Aparicio

Rosa Isabel Fernandez Chimeno

Antonio Medarde Fernandez

Librada Maria Canedo Hernandez

Francisco Romero Millan

Julia Perez Baz

Carmen Belen Gil Ayuso-Gontan

Diana Alonso Gordillo

Maria Del Monte Millan

Daniel Perez Fernandez

Maria Isabel Cadavid Torres

Jose Brea Floriani

Maria Isabel Loza Garcia

Rocío Benitez Fernandez

Eduardo Berenguer Peinado

Pilar Sánchez Testillano

Yolanda Pérez Pérez

Elena Carneros García

The present invention relates to a series of compounds having a structural benzothiazole-benzamide core with capacity to inhibit the LRRK2 enzyme, due to which the invention also relates to the use of these compounds for treating neurodegenerative diseases in which this enzyme is involved, such as Parkinson's Disease or Alzheimer's Disease.

LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases

The present invention relates to a series of substituted purine derivatives capable of inhibiting CDC7 kinase activity and, as such, suitable for use in the treatment of neurological diseases such as, inter alia, Alzheimer's disease, amyotrophic lateral sclerosis or frontotemporal dementia, involving hyperphosphorylation of TDP-43 and the subsequent formation of aggregates, induced by CDC7.

CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions

The present invention relates to a family of S-substituted quinazoline derivatives that inhibitors of the enzyme phosphodiesterase 7 (PDE7), useful for the treatment or prevention of diseases mediated by said enzyme, especially inflammatory, neurodegenerative, neurological, psychiatric and/or autoimmune diseases.

S-substituted quinazolines and their therapeutic applications for the treatment of diseases mediated by PDE7

The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.

Heterocyclic GSK-3 allosteric modulators

The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3&#x3b2;, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus. 

GSK-3 inhibitors

The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds. 

[1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases

Provided are thiadiazolidine compounds of formula I wherein Ris an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a &#x2014;C(O)&#x2014; and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.

The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.

Use of collismycin and derivatives thereof as oxidative stress inhibitors

The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the &#x3b2;-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.

Acetylcholinesterase dual inhibitors

Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Enzyme inhibitors

Compounds of general formula (I):where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Heterocyclic inhibitors of glycogen synthase kinase GSK-3

Compounds and their therapeutic use

Growing community of inventors

Madrid, Spain

Ana Martinez Gil